Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
November 8, 2022 4:04 PM ESTCoherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $57.27 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
... More